je.st
news
Home
› Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration
Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration
2014-02-05 07:17:03| drugdiscoveryonline News Articles
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, recently announced that it has elected to retain the United States development and commercial rights to the isocitratedehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism
Tags: rights
under
development
program
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||